Patient with JIA with acute exacerbation/follow-up | JIA group (n=6) | JIA follow-up (n=6) | HD (n=6) | |
---|---|---|---|---|
CD3+ | 1.1/1.3 | 1.73±0.68 (1.60; 1.10 to 2.80) | 1.04±0.49 (0.98; 0.51 to 1.72)++ | 2.18±0.36 (2.0; 1.90 to 2.70) |
CD3+HLA-DR+ | 0.06/0.03 | 0.09±0.01 (0.09; 0.08 to 0.11) | 0.09±0.05 (0.11; 0.03 to 0.16) | 0.13±0.03 (0.12; 0.11 to 0.19)xx |
CD3+CD4+ | 0.72/0.93 | 0.94±0.48 (0.79; 0.55 to 1.83) | 0.59±0.31 (0.62; 0.24 to 0.96)++ | 1.31±0.35 (1.24; 0.88 to 1.84) |
CD4+CD25+CD62L+ | 0.12/0.04 | 0.19±0.18 (0.15; 0.03 to 0.52) | 0.14±0.09 (0.13; 0.05 to 0.26) | 0.25±0.08 (0.23; 0.15 to 0.35) |
CD4+CD28+ | 0.20/0.31 | 0.90±0.46 (0.76; 0.53 to 1.73)*** | 0.57±0.29 (0.62; 0.23 to 0.90)+++ | 1.27±0.34 (1.22; 0.84 to 1.78)xx |
CD4+CD28+CD45RA+ | 0.15/0.16 | 0.33±0.24 (0.25; 0.001 to 0.62) | 0.31±0.15 (0.35; 0.13 to 0.46)++ | 0.49±0.012 (0.45; 0.34 to 0.63)xx |
CD4+CD45RA+CD62L+ | 0.22/0.04 | 0.39±0.24 (0.43; 0.001 to 1.14) | 0.19±0.08 (0.19; 0.09 to 0.28) | 0.34±0.32 (0.16, 0.19 to 0.61) |
CD4+CD45RO+ | 0.12/0.15 | 0.08±0.07 (0.06; 0.01 to 0.22) | 0.22±0.13 (0.23; 0.07 to 0.38) | 0.15±0.11 (0.17; 0.001 to 0.29) |
CD3+CD8+ | 0.34/0.37 | 0.50±0.19 (0.49; 0.27 to 0.73) | 0.41±0.18 (0.37; 0.21 to 0.65)++ | 0.78±0.14 (0.76; 0.63 to 0.96) |
CD8+CD28+ | 0.28/0.32 | 0.41±0.16 (0.41; 0.18 to 0.64) | 0.31±0.15 (0.26; 0.17 to 0.51)++ | 0.61±0.11 (0.64; 0.47 to 0.75) |
CD8+CD28+CD45RA+ | 0.30/0.25 | 0.57±0.51 (0.43; 0.01 to 1.44) | 0.29±0.13 (0.27; 0.16 to 0.47)+ | 0.66±0.24 (0.63; 0.41 to 1.06) |
CD8+CD45RA+CD62L+ | 0.07/0.09 | 0.31±0.25 (0.20; 0.05 to 0.53)*** | 0.19±0.07 (0.16; 0.12 to 0.29) | 0.32±0.29 (0.13; 0.19 to 0.52) |
CD8+CD45RO+ | 0.38/0.90 | 0.23±0.12 (0.23; 0.03 to 0.41)** | 0.70±0.30 (0.61; 0.30 to 1.13) | 0.41±0.25 (0.42; 0.001 to 0.69) |